Clinical Trial: A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07266324) titled 'A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.' on Nov. 17.

Brief Summary: The goal of this clinical trial is to evaluate the safety and effects of a new drug called BMB-101 in people with Prader-Willi Syndrome (PWS). This study is designed as a multi-centre, double-blind, randomized, placebo controlled 2-part study with a blinded main phase followed up an open label extension phase.

Study Start Date: Jan., 2026

Study Type: INTERVENTIONAL

Condition: Prader-Willi Syndrome

Intervention: DRUG: BMB-101

Participants will receive weekly ascending oral d...